EIF4A3依赖的无义介导衰变缓冲AML1-ETO9a剂量并影响t(8;21)急性髓系白血病结局
本研究在t(8;21)急性髓系白血病中鉴定出无义介导的mRNA衰变(NMD)是AE9a亚型的特异性缓冲机制。ETO9a盒外显子包含引入提前终止密码子产生NMD敏感转录本。在原代t(8;21) AML CD34⁺细胞中AE9a包含与NMD因子表达负相关,高EIF4A3表达与t(8;21) AML总生存改善相关。抑制NMD增加AE9a,而过表达EIF4A3降低AE9a并抑制白血病细胞生长、增强伊达比星敏感性。
要点
- NMD是AE9a剂量的特异性缓冲机制,ETO9a外显子包含引入提前终止密码子。
- 高EIF4A3表达与t(8;21) AML总生存改善相关,其他AML亚型未见。
- 抑制NMD增加AE9a,过表达EIF4A3降低AE9a并增强伊达比星敏感性。
核心结论
- EIF4A3依赖的NMD是t(8;21) AML中缓冲AE9a剂量、调节白血病细胞适应性和化疗敏感性的检查点。
研究设计与样本
- 研究采用原代t(8;21) AML CD34⁺造血干祖细胞、t(8;21) AML细胞系和患者原代细胞进行实验。
主要发现
- 在原代t(8;21) AML CD34⁺细胞中,AE9a包含与NMD因子表达呈负相关。
- 高EIF4A3表达与t(8;21) AML总生存改善相关,但在其他AML亚型中无此关联。
- 药物抑制SMG1或EIF4A3及遗传敲低NMD因子增加t(8;21) AML细胞系和患者原代细胞中AE9a丰度、胞质转录本积累和AE9a蛋白。
- 过表达EIF4A3降低AE9a RNA和蛋白,抑制t(8;21) AML细胞生长,保留健康CD34⁺祖细胞扩增,并增强伊达比星敏感性。
临床怎么用
- EIF4A3表达水平可能作为t(8;21) AML预后分层和化疗敏感性预测的潜在生物标志物。
- 靶向NMD通路(如SMG1或EIF4A3)可能成为t(8;21) AML的治疗策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
t(8;21) acute myeloid leukemia (AML) is driven by AML1-ETO, which undergoes alternative splicing to generate AML1-ETO9a (AE9a), a truncated isoform with enhanced leukemogenic activity. Although t(8;21) AML is considered favorable-risk, clinical outcomes are heterogeneous, and AE9a expression varies markedly among patients. How cells restrain this oncogenic isoform remains unclear. Here, we identify nonsense-mediated mRNA decay (NMD) as an isoform-specific buffer of AE9a dosage. Inclusion of the ETO9a cassette exon introduces premature termination codons and generates an NMD-sensitive transcript. In primary t(8;21) AML CD34⁺ hematopoietic stem and progenitor cells, AE9a inclusion inversely correlated with NMD-factor expression, and high EIF4A3 expression was associated with improved overall survival specifically in t(8;21) AML, but not in other AML subtypes. Pharmacological inhibition of SMG1 or EIF4A3 and genetic depletion of NMD factors increased AE9a abundance in t(8;21) AML cell lines and primary patient cells, with cytoplasmic transcript accumulation and increased AE9a protein. Conversely, EIF4A3 overexpression reduced AE9a RNA and protein, restrained t(8;21) AML cell growth, spared healthy CD34⁺ progenitor expansion, and enhanced idarubicin sensitivity. These findings define EIF4A3-dependent NMD as a checkpoint linking RNA surveillance to oncogenic fusion-isoform dosage, leukemic fitness, and chemosensitivity in t(8;21) AML, providing a mechanistic explanation for clinical heterogeneity in t(8;21) AML. EIF4A3-dependent NMD buffers AE9a dosage and modulates t(8;21) AML cell fitness and chemosensitivity: Schematic model summarizing the proposed AE9a-NMD axis in t(8;21) AML. Alternative splicing of AML1-ETO generates the ETO9a cassette exon, producing a PTC-containing AE9a transcript. After nuclear export, ribosome engagement with the PTC-containing AE9a mRNA recruits the NMD machinery, including UPF factors, SMG factors, DHX34, and the exon-junction complex component EIF4A3. Efficient NMD promotes AE9a mRNA decay and limits AE9a protein accumulation. High EIF4A3/NMD activity therefore lowers AE9a dosage, restrains t(8;21) AML cell proliferation, enhances chemosensitivity to idarubicin, and is associated with improved patient survival. Conversely, impaired NMD activity permits AE9a accumulation and may increase leukemic fitness. This model defines an isoform-specific, NMD-buffered oncogenic dosage checkpoint in t(8;21) AML.
引用
- Zhang M, Li Y, Zhang B, et al. EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage and modulates outcome in t(8;21) acute myeloid leukemia. Leukemia. 2026. PMID: 42448936. doi:10.1038/s41375-026-03051-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。